Loading viewer...
investor_presentation
Format: PDF investor_presentation
LAVA Therapeutics presents its proprietary Gammabody® platform for gamma-delta T cell engagers targeting multiple cancer types including mCRPC, AML, and NSCLC. The company's lead program LAVA-1207 is enrolling in Phase 1/2a trials with strategic partnerships from Pfizer and Johnson & Johnson, backed by $95 million in cash with runway into 2026.
investor_presentation
16 Pages
AAR Corp.
ANZ ESG Presentation 2020 - Environmental Social Governance
investor_presentationinvestor_presentation
51 Pages
Australia and New Zealand Banking Group
Phibro Animal Health (PAHC) 2022 Company Overview
investor_presentationinvestor_presentation
30 Pages
Phibro Animal Health Corporation